Symbols / ENTA $13.14 +1.31% Enanta Pharmaceuticals, Inc.
ENTA Chart
About
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 381.31M |
| Enterprise Value | 388.65M | Income | -71.54M | Sales | 66.98M |
| Book/sh | 4.36 | Cash/sh | 6.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 120 | IPO | — |
| P/E | — | Forward P/E | -5.95 | PEG | — |
| P/S | 5.69 | P/B | 3.01 | P/C | — |
| EV/EBITDA | -5.70 | EV/Sales | 5.80 | Quick Ratio | 4.34 |
| Current Ratio | 4.44 | Debt/Eq | 152.60 | LT Debt/Eq | — |
| EPS (ttm) | -3.21 | EPS next Y | -2.21 | EPS Growth | — |
| Revenue Growth | 9.80% | Earnings | 2026-05-11 | ROA | -13.47% |
| ROE | -60.01% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -60.45% | Profit Margin | -106.80% | Shs Outstand | 29.02M |
| Shs Float | 20.20M | Short Float | 8.93% | Short Ratio | 11.15 |
| Short Interest | — | 52W High | 17.15 | 52W Low | 4.09 |
| Beta | 1.00 | Avg Volume | 193.92K | Volume | 112.82K |
| Target Price | $18.50 | Recom | Buy | Prev Close | $12.97 |
| Price | $13.14 | Change | 1.31% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-11-14 | init | JP Morgan | — → Overweight | $17 |
| 2025-09-30 | main | WestPark Capital | Buy → Buy | $28 |
| 2025-09-15 | main | Evercore ISI Group | Outperform → Outperform | $12 |
| 2025-09-02 | init | WestPark Capital | — → Buy | $24 |
| 2025-08-12 | main | JMP Securities | Market Outperform → Market Outperform | $25 |
| 2025-06-03 | main | JMP Securities | Market Outperform → Market Outperform | $24 |
| 2025-05-14 | main | JMP Securities | Market Outperform → Market Outperform | $23 |
| 2025-02-11 | reit | JMP Securities | Market Outperform → Market Outperform | $21 |
| 2025-02-11 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-12-24 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-11-26 | main | Baird | Outperform → Outperform | $20 |
| 2024-11-26 | reit | JMP Securities | Market Outperform → Market Outperform | $21 |
| 2024-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2024-10-09 | reit | JMP Securities | Market Outperform → Market Outperform | $22 |
| 2024-09-27 | reit | JMP Securities | Market Outperform → Market Outperform | $22 |
| 2024-08-06 | main | JP Morgan | Underweight → Underweight | $10 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2024-05-07 | main | HC Wainwright & Co. | Buy → Buy | $27 |
- Trading Systems Reacting to (ENTA) Volatility - Stock Traders Daily Sun, 05 Apr 2026 14
- Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average - Should You Sell? - MarketBeat Fri, 03 Apr 2026 07
- What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - finance.yahoo.com hu, 12 Feb 2026 08
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st Sat, 20 Dec 2025 08
- Four Enanta posters spotlight oral STAT6 inhibitor data in asthma research - Stock Titan Mon, 30 Mar 2026 11
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat Fri, 03 Apr 2026 08
- Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update - Stocktwits Mon, 29 Sep 2025 07
- Jefferies reiterates Enanta Pharmaceuticals stock rating on patent case By Investing.com - Investing.com Canada ue, 31 Mar 2026 21
- Responsive Playbooks and the ENTA Inflection - Stock Traders Daily ue, 03 Mar 2026 09
- Early data on Enanta's EDP-978 hint at once-daily dosing potential - Stock Titan ue, 10 Feb 2026 08
- Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - finance.yahoo.com Mon, 09 Feb 2026 08
- How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - Stock Traders Daily Wed, 25 Mar 2026 07
- Vanguard disaggregates holdings; reports 0 shares of Enanta (ENTA) - Stock Titan hu, 26 Mar 2026 07
- Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Rodman & Renshaw - MarketBeat hu, 26 Mar 2026 07
- Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade - finance.yahoo.com Fri, 21 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
65.32
-3.42%
|
67.64
-14.61%
|
79.20
-8.07%
|
86.16
|
| Operating Revenue |
|
65.32
-3.42%
|
67.64
-14.61%
|
79.20
-8.07%
|
86.16
|
| Operating Expense |
|
150.67
-20.42%
|
189.33
-12.52%
|
216.41
+3.05%
|
210.00
|
| Research And Development |
|
106.74
-18.81%
|
131.48
-19.60%
|
163.52
-0.61%
|
164.52
|
| Selling General And Administration |
|
43.93
-24.06%
|
57.85
+9.38%
|
52.89
+16.28%
|
45.48
|
| General And Administrative Expense |
|
43.93
-24.06%
|
57.85
+9.38%
|
52.89
+16.28%
|
45.48
|
| Other Gand A |
|
43.93
-24.06%
|
57.85
+9.38%
|
52.89
+16.28%
|
45.48
|
| Total Expenses |
|
150.67
-20.42%
|
189.33
-12.52%
|
216.41
+3.05%
|
210.00
|
| Operating Income |
|
-85.35
+29.86%
|
-121.69
+11.31%
|
-137.21
-10.79%
|
-123.84
|
| Total Operating Income As Reported |
|
-85.35
+29.86%
|
-121.69
+11.31%
|
-137.21
-10.79%
|
-123.84
|
| EBITDA |
|
-71.28
+31.80%
|
-104.51
+15.36%
|
-123.48
-3.57%
|
-119.22
|
| Normalized EBITDA |
|
-71.32
+31.81%
|
-104.58
+15.30%
|
-123.48
-3.50%
|
-119.30
|
| Reconciled Depreciation |
|
4.59
+96.32%
|
2.34
-1.48%
|
2.37
-20.25%
|
2.97
|
| EBIT |
|
-75.87
+28.99%
|
-106.85
+15.10%
|
-125.85
-2.99%
|
-122.19
|
| Total Unusual Items |
|
0.04
-46.58%
|
0.07
|
—
|
0.08
|
| Total Unusual Items Excluding Goodwill |
|
0.04
-46.58%
|
0.07
|
—
|
0.08
|
| Net Income |
|
-81.89
+29.43%
|
-116.05
+13.28%
|
-133.82
-9.91%
|
-121.75
|
| Pretax Income |
|
-83.55
+29.07%
|
-117.79
+10.08%
|
-131.00
-7.21%
|
-122.19
|
| Net Non Operating Interest Income Expense |
|
1.76
-54.02%
|
3.83
-38.35%
|
6.21
+294.91%
|
1.57
|
| Interest Expense Non Operating |
|
7.68
-29.79%
|
10.94
+112.51%
|
5.15
|
0.00
|
| Net Interest Income |
|
1.76
-54.02%
|
3.83
-38.35%
|
6.21
+294.91%
|
1.57
|
| Interest Expense |
|
7.68
-29.79%
|
10.94
+112.51%
|
5.15
|
0.00
|
| Interest Income Non Operating |
|
9.44
-36.07%
|
14.77
+30.02%
|
11.36
+622.19%
|
1.57
|
| Interest Income |
|
9.44
-36.07%
|
14.77
+30.02%
|
11.36
+622.19%
|
1.57
|
| Other Income Expense |
|
0.04
-46.58%
|
0.07
|
—
|
0.08
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
0.08
|
| Gain On Sale Of Security |
|
0.04
-46.58%
|
0.07
|
—
|
0.08
|
| Tax Provision |
|
-1.66
+4.76%
|
-1.74
-161.79%
|
2.82
+751.50%
|
-0.43
|
| Tax Rate For Calcs |
|
0.00
+33.33%
|
0.00
-92.86%
|
0.00
+5150.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
-28.77%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-81.89
+29.43%
|
-116.05
+13.28%
|
-133.82
-9.91%
|
-121.75
|
| Net Income From Continuing Operation Net Minority Interest |
|
-81.89
+29.43%
|
-116.05
+13.28%
|
-133.82
-9.91%
|
-121.75
|
| Net Income From Continuing And Discontinued Operation |
|
-81.89
+29.43%
|
-116.05
+13.28%
|
-133.82
-9.91%
|
-121.75
|
| Net Income Continuous Operations |
|
-81.89
+29.43%
|
-116.05
+13.28%
|
-133.82
-9.91%
|
-121.75
|
| Normalized Income |
|
-81.93
+29.44%
|
-116.12
+13.23%
|
-133.82
-9.83%
|
-121.84
|
| Net Income Common Stockholders |
|
-81.89
+29.43%
|
-116.05
+13.28%
|
-133.82
-9.91%
|
-121.75
|
| Diluted EPS |
|
-3.84
+29.93%
|
-5.48
+14.11%
|
-6.38
-7.95%
|
-5.91
|
| Basic EPS |
|
-3.84
+29.93%
|
-5.48
+14.11%
|
-6.38
-7.95%
|
-5.91
|
| Basic Average Shares |
|
21.34
+0.85%
|
21.16
+0.90%
|
20.97
+1.78%
|
20.60
|
| Diluted Average Shares |
|
21.34
+0.85%
|
21.16
+0.90%
|
20.97
+1.78%
|
20.60
|
| Diluted NI Availto Com Stockholders |
|
-81.89
+29.43%
|
-116.05
+13.28%
|
-133.82
-9.91%
|
-121.75
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
280.73
-25.47%
|
376.65
-18.52%
|
462.27
+23.14%
|
375.41
|
| Current Assets |
|
204.34
-31.85%
|
299.85
-29.08%
|
422.79
+35.63%
|
311.71
|
| Cash Cash Equivalents And Short Term Investments |
|
188.86
-23.90%
|
248.19
-32.91%
|
369.91
+48.42%
|
249.23
|
| Cash And Cash Equivalents |
|
32.30
-13.25%
|
37.23
-56.40%
|
85.39
+94.09%
|
43.99
|
| Other Short Term Investments |
|
156.57
-25.78%
|
210.95
-25.86%
|
284.52
+38.63%
|
205.24
|
| Receivables |
|
6.88
-82.19%
|
38.65
-2.46%
|
39.62
-19.21%
|
49.04
|
| Accounts Receivable |
|
6.88
+3.55%
|
6.65
-22.85%
|
8.61
-57.60%
|
20.32
|
| Taxes Receivable |
|
0.00
-100.00%
|
32.00
+3.21%
|
31.00
+7.96%
|
28.72
|
| Prepaid Assets |
|
—
|
—
|
—
|
13.45
|
| Restricted Cash |
|
0.00
-100.00%
|
0.61
|
0.00
|
—
|
| Other Current Assets |
|
8.59
-30.80%
|
12.41
-6.41%
|
13.26
-1.35%
|
13.45
|
| Total Non Current Assets |
|
76.40
-0.53%
|
76.80
+94.51%
|
39.48
-38.01%
|
63.70
|
| Net PPE |
|
72.94
-0.55%
|
73.35
+111.29%
|
34.71
+16.69%
|
29.75
|
| Gross PPE |
|
96.75
-1.67%
|
98.39
+68.31%
|
58.46
+13.28%
|
51.61
|
| Accumulated Depreciation |
|
-23.80
+4.96%
|
-25.05
-5.48%
|
-23.75
-8.63%
|
-21.86
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
21.00
-0.06%
|
21.01
+2.06%
|
20.59
+13.12%
|
18.20
|
| Construction In Progress |
|
0.00
-100.00%
|
22.75
+1686.96%
|
1.27
-50.20%
|
2.56
|
| Other Properties |
|
37.55
-7.65%
|
40.66
+78.37%
|
22.79
-3.31%
|
23.57
|
| Leases |
|
38.20
+173.35%
|
13.97
+1.24%
|
13.80
+89.72%
|
7.28
|
| Investments And Advances |
|
—
|
—
|
0.00
-100.00%
|
29.29
|
| Other Non Current Assets |
|
3.45
-0.06%
|
3.45
-27.60%
|
4.77
+2.29%
|
4.66
|
| Total Liabilities Net Minority Interest |
|
216.01
-12.84%
|
247.84
+0.94%
|
245.54
+354.06%
|
54.08
|
| Current Liabilities |
|
48.55
-15.61%
|
57.53
-8.36%
|
62.79
+110.50%
|
29.83
|
| Payables And Accrued Expenses |
|
14.70
-31.79%
|
21.55
-3.95%
|
22.44
-16.71%
|
26.94
|
| Payables |
|
1.95
-75.66%
|
8.00
+95.31%
|
4.10
-31.72%
|
6.00
|
| Accounts Payable |
|
1.95
-75.66%
|
8.00
+95.31%
|
4.10
-31.72%
|
6.00
|
| Current Accrued Expenses |
|
12.75
-5.88%
|
13.55
-26.13%
|
18.34
-12.40%
|
20.94
|
| Current Debt And Capital Lease Obligation |
|
3.15
+106.43%
|
1.52
-71.11%
|
5.28
+82.46%
|
2.89
|
| Current Capital Lease Obligation |
|
3.15
+106.43%
|
1.52
-71.11%
|
5.28
+82.46%
|
2.89
|
| Other Current Liabilities |
|
30.71
-10.89%
|
34.46
-1.75%
|
35.08
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
167.46
-12.00%
|
190.30
+4.13%
|
182.75
+653.65%
|
24.25
|
| Long Term Debt And Capital Lease Obligation |
|
54.76
+1.51%
|
53.94
+153.99%
|
21.24
-5.07%
|
22.37
|
| Long Term Capital Lease Obligation |
|
54.76
+1.51%
|
53.94
+153.99%
|
21.24
-5.07%
|
22.37
|
| Other Non Current Liabilities |
|
111.39
-17.49%
|
135.01
-15.67%
|
160.09
+35162.56%
|
0.45
|
| Preferred Securities Outside Stock Equity |
|
1.31
-2.89%
|
1.35
-5.13%
|
1.42
+0.00%
|
1.42
|
| Stockholders Equity |
|
64.72
-49.76%
|
128.81
-40.57%
|
216.74
-32.55%
|
321.33
|
| Common Stock Equity |
|
64.72
-49.76%
|
128.81
-40.57%
|
216.74
-32.55%
|
321.33
|
| Capital Stock |
|
0.21
+0.94%
|
0.21
+0.47%
|
0.21
+1.44%
|
0.21
|
| Common Stock |
|
0.21
+0.94%
|
0.21
+0.47%
|
0.21
+1.44%
|
0.21
|
| Share Issued |
|
21.39
+0.91%
|
21.19
+0.64%
|
21.06
+1.29%
|
20.79
|
| Ordinary Shares Number |
|
21.39
+0.91%
|
21.19
+0.64%
|
21.06
+1.29%
|
20.79
|
| Additional Paid In Capital |
|
469.77
+4.08%
|
451.34
+6.27%
|
424.69
+6.70%
|
398.03
|
| Retained Earnings |
|
-404.93
-25.35%
|
-323.04
-56.06%
|
-207.00
-182.86%
|
-73.18
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.34
-212.25%
|
0.30
+125.72%
|
-1.17
+68.47%
|
-3.72
|
| Other Equity Adjustments |
|
-0.34
-212.25%
|
0.30
+125.72%
|
-1.17
+68.47%
|
-3.72
|
| Total Equity Gross Minority Interest |
|
64.72
-49.76%
|
128.81
-40.57%
|
216.74
-32.55%
|
321.33
|
| Total Capitalization |
|
64.72
-49.76%
|
128.81
-40.57%
|
216.74
-32.55%
|
321.33
|
| Working Capital |
|
155.78
-35.71%
|
242.32
-32.69%
|
360.00
+27.71%
|
281.89
|
| Invested Capital |
|
64.72
-49.76%
|
128.81
-40.57%
|
216.74
-32.55%
|
321.33
|
| Total Debt |
|
57.90
+4.39%
|
55.47
+109.21%
|
26.51
+4.95%
|
25.26
|
| Capital Lease Obligations |
|
57.90
+4.39%
|
55.47
+109.21%
|
26.51
+4.95%
|
25.26
|
| Net Tangible Assets |
|
64.72
-49.76%
|
128.81
-40.57%
|
216.74
-32.55%
|
321.33
|
| Tangible Book Value |
|
64.72
-49.76%
|
128.81
-40.57%
|
216.74
-32.55%
|
321.33
|
| Available For Sale Securities |
|
—
|
—
|
—
|
29.29
|
| Investmentin Financial Assets |
|
—
|
—
|
0.00
-100.00%
|
29.29
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-19.27
+75.53%
|
-78.76
+23.64%
|
-103.15
-21.67%
|
-84.78
|
| Cash Flow From Continuing Operating Activities |
|
-19.27
+75.53%
|
-78.76
+23.64%
|
-103.15
-21.67%
|
-84.78
|
| Net Income From Continuing Operations |
|
-81.89
+29.43%
|
-116.05
+13.28%
|
-133.82
-9.91%
|
-121.75
|
| Depreciation Amortization Depletion |
|
4.59
+96.32%
|
2.34
-1.48%
|
2.37
-20.25%
|
2.97
|
| Depreciation |
|
4.59
|
—
|
—
|
—
|
| Depreciation And Amortization |
|
4.59
+96.32%
|
2.34
-1.48%
|
2.37
-20.25%
|
2.97
|
| Other Non Cash Items |
|
-0.95
-144.44%
|
2.14
+140.85%
|
-5.24
-464.37%
|
-0.93
|
| Stock Based Compensation |
|
18.57
-30.71%
|
26.80
-5.04%
|
28.22
+4.62%
|
26.97
|
| Deferred Tax |
|
—
|
—
|
0.00
|
0.00
|
| Deferred Income Tax |
|
—
|
—
|
0.00
|
0.00
|
| Operating Gains Losses |
|
0.01
-62.50%
|
0.02
-89.33%
|
0.15
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.01
-62.50%
|
0.02
-89.33%
|
0.15
|
0.00
|
| Change In Working Capital |
|
39.91
+459.73%
|
7.13
-11.14%
|
8.02
+18.19%
|
6.79
|
| Change In Receivables |
|
31.76
+3164.44%
|
0.97
-89.67%
|
9.42
-20.15%
|
11.79
|
| Changes In Account Receivables |
|
-0.24
-111.99%
|
1.97
-83.19%
|
11.70
+259.24%
|
3.26
|
| Change In Prepaid Assets |
|
3.82
+349.76%
|
0.85
+367.03%
|
0.18
-75.50%
|
0.74
|
| Change In Payables And Accrued Expense |
|
-1.25
+79.32%
|
-6.06
-63.39%
|
-3.71
+39.31%
|
-6.11
|
| Change In Accrued Expense |
|
0.06
+101.03%
|
-5.65
-120.72%
|
-2.56
-73.19%
|
-1.48
|
| Change In Payable |
|
-1.31
-216.67%
|
-0.41
+64.03%
|
-1.15
+75.16%
|
-4.63
|
| Change In Account Payable |
|
-1.31
-216.67%
|
-0.41
+64.03%
|
-1.15
+75.16%
|
-4.63
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.60
|
| Change In Other Current Assets |
|
4.31
-36.66%
|
6.80
+51.53%
|
4.49
+7.65%
|
4.17
|
| Change In Other Current Liabilities |
|
1.27
-72.25%
|
4.56
+293.47%
|
-2.36
+38.11%
|
-3.81
|
| Investing Cash Flow |
|
40.35
-30.72%
|
58.23
+208.69%
|
-53.58
-197.60%
|
54.90
|
| Cash Flow From Continuing Investing Activities |
|
40.35
-30.72%
|
58.23
+208.69%
|
-53.58
-197.60%
|
54.90
|
| Net PPE Purchase And Sale |
|
-12.90
+28.15%
|
-17.95
-98.15%
|
-9.06
-326.26%
|
-2.12
|
| Purchase Of PPE |
|
-12.90
+28.15%
|
-17.95
-98.15%
|
-9.06
-326.26%
|
-2.12
|
| Capital Expenditure |
|
-12.90
+28.15%
|
-17.95
-98.15%
|
-9.06
-326.26%
|
-2.12
|
| Net Investment Purchase And Sale |
|
53.24
-30.11%
|
76.18
+271.12%
|
-44.52
-178.08%
|
57.02
|
| Purchase Of Investment |
|
-209.63
+31.78%
|
-307.28
+17.71%
|
-373.39
-117.79%
|
-171.45
|
| Sale Of Investment |
|
262.87
-31.45%
|
383.46
+16.60%
|
328.87
+43.95%
|
228.47
|
| Financing Cash Flow |
|
-26.62
+3.65%
|
-27.63
-113.94%
|
198.13
+889.00%
|
20.03
|
| Cash Flow From Continuing Financing Activities |
|
-26.62
+3.65%
|
-27.63
-113.94%
|
198.13
+889.00%
|
20.03
|
| Net Issuance Payments Of Debt |
|
—
|
-27.48
|
0.00
|
0.00
|
| Repayment Of Debt |
|
—
|
-27.48
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
-27.48
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
-27.48
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.14
-1.36%
|
0.15
-93.34%
|
2.21
-89.62%
|
21.26
|
| Net Other Financing Charges |
|
-26.76
+3.64%
|
-27.77
-114.18%
|
195.92
+16041.25%
|
-1.23
|
| Changes In Cash |
|
-5.54
+88.49%
|
-48.16
-216.33%
|
41.39
+520.16%
|
-9.85
|
| Beginning Cash Position |
|
41.20
-53.89%
|
89.36
+86.31%
|
47.96
-17.04%
|
57.81
|
| End Cash Position |
|
35.66
-13.45%
|
41.20
-53.89%
|
89.36
+86.31%
|
47.96
|
| Free Cash Flow |
|
-32.17
+66.74%
|
-96.71
+13.81%
|
-112.21
-29.12%
|
-86.91
|
| Interest Paid Supplemental Data |
|
8.79
-24.90%
|
11.71
+489.33%
|
1.99
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.11
-54.77%
|
0.24
-95.08%
|
4.90
|
0.00
|
| Amortization Of Securities |
|
0.50
+144.20%
|
-1.14
+60.15%
|
-2.86
-343.89%
|
1.17
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-26 View
- 42026-03-13 View
- 42026-03-13 View
- 42026-03-13 View
- 42026-03-13 View
- 42026-03-13 View
- 42026-03-13 View
- 8-K2026-03-12 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 10-Q2026-02-11 View
- 8-K2026-02-09 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-12-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|